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Abstract
Experimental autoimmune encephalomyelitis (EAE) is - in certain aspects - regarded as an animal model of the
human CNS autoimmune disease multiple sclerosis (MS). While in EAE CNS-autoantigen-specific immunity is
induced in a defined way, the initial processes leading to CNS autoimmunity in humans are so far unknown.
Despite essential restrictions, which exist regarding the interpretation of EAE data towards MS, EAE might be a
useful model to study certain basic aspects of CNS autoimmunity. Studies in MS have demonstrated that
established autoimmune pathology can be critically influenced by environmental factors, in particular viral and
bacterial infections. To investigate this interaction, EAE as an instrument to study CNS autoimmunity under defined
conditions appears to be a suitable experimental tool. For this reason, we here investigated the influence of the
Toll-like-receptor (TLR) ligand CpG oligonucleotide (CpG) on already established CNS autoimmunity in murine
proteolipid protein (PLP)-induced EAE in SJL mice. CpG were found to co-stimulate PLPp-specific IFN-g production
in the peripheral immune system and in the CNS. However, CpG induced Interleukin (IL)-17 production in the
inflamed CNS both alone and in combination with additional PLPp stimulation. These findings might indicate a
mechanism by which systemic infections and the microbial stimuli associated with them may influence already
existing CNS autoimmune pathology.
Background
Research on the role of T cells in CNS autoimmune dis-
ease both in human diseases as well as in their experi-
mental animal models currently centers on the
endogenous requirements which are necessary for T cell
activation as well as on the exogenous factors which
trigger it. Among the environmental elements, which
can influence this process (both in a positive and nega-
tive way), infections are considered important [1;2].
These include both viral and bacterial infections as well
as the pathogenic factors which are associated with
them. The potential role of microbial pathogens in trig-
gering autoimmune disease has been extensively studied
both in humans as well as in experimental animal mod-
els. As an example for one of many infectious agents
which have been discussed as the cause of MS, a
positive association between Epstein-Barr virus (EBV)
infection and increased risk of developing MS thereafter
has been broadly discussed [3]. Such clinical observa-
tions have been supported by basic observations from
cell culture models which try to explain how infectious
agents can affect the CNS and facilitate key steps in MS
pathogenesis, e.g. through creating a local proinflamma-
tory milieu in the early stages of disease [4]. In the EAE
mouse model, there is currently increasing evidence for
a critical role of commensal gut microbiota in the initia-
tion of CNS autoimmunity, as demonstrated by experi-
ments in which reduction of the commensal microflora
by antibiotic treatment inhibits the development of EAE
[5]. However, despite the fact that disease progression
or relapse is clinically to the same extent associated
with bacterial or viral infection as the beginning of dis-
ease, in particular in the case of MS [6-9], the influence
of these pathogenic conditions on already established
autoimmune disease has received less attention. In EAE
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ligand, has been shown to be able to induce relapses via
antigen presenting cell (APC)-dependent activation of
autoantigen-specific T cells [10].
When studying the impact of infection on ongoing
CNS autoimmunity, a differentiated setup has to be cho-
sen. First, systemic effects of a microbial stimulus on the
autoimmune T cell population might differ from its
effects in the CNS [11;12]. Second, different T cell popu-
lations might be affected in a distinct way, which might
also be different in the periphery and in the inflamed
CNS. T cell populations that are currently implied in
CNS autoimmune pathology are Th1 and Th17 cells,
which are characterized by the production of IFN-g and
IL-17, respectively [13]. Both cytokines are important
mediators of disease and tissue damage in CNS autoim-
munity, albeit with different roles in the autoimmune
process and different resulting pathology [14-16].
For this reason, it was the purpose of this study to
investigate the influence of CpG as a paradigm of a
microbial stimulus which is able to activate both APC
[17] as well as T cells directly [18] on the PLPp-specific
T cell cytokine production in EAE in SJL mice, in parti-
cular in regard of IFN-g and IL-17.
Methods
Animals, antigens and treatments
Female SJL/J mice at age 6-8 wk were purchased from
Charles River (Sulzfeld, Germany) and maintained at the
local animal facilities. Mice were divided in two groups
and immunized subcutaneously either with 100 μg PLP
peptide amino acids 139-151 (PLPp, Biotrend, Cologne,
Germany) and 100 μg CpG oligonucleotide 1760 with
the sequence ATAATCGACGTTCAAGCAAG (CpG,
Eurofins MWG Operon, Ebersberg, Germany) in incom-
plete Freund’s adjuvant (IFA, Difco, Detroit, USA) or
with 100 μgP L P pi nc o m p l e t eF r e u n d ’sa d j u v a n t( C F A ,
Difco, Detroit, USA). Mice immunized with PLPp in
CFA were additionally given two intraperitoneal applica-
tions of 400 ng pertussis toxin (PTX, Sigma, Deisenho-
fen, Germany) in 500 μl phosphate buffered saline (PBS)
on day 0 and day 2 after immunization. PLPp/CFA was
prepared by mixing PLPp in CFA yielding a final con-
centration of 1 mg/ml. PLPp/CpG/IFA was prepared by
mixing PLPp and CpG in IFA yielding a final concentra-
tion of 1 mg/ml for both agents. Mice were assessed
daily for the development of paralytic symptoms, and
the severity of disease was recorded according to a stan-
dard scale: grade 1, floppy tail; grade 2: hind leg weak-
ness; grade 3: full hind leg paralysis; grade 4:
q u a d r i p l e g i a ;a n dg r a d e5 :d e a t h .A c c e s st of o o da n d
drinking water was ensured for all mice, including those
with paralysis. All animal experiments were approved by
the local authorities for animal experimentation.
Cell preparation from the organs tested
After sacrificing the animals with isoflurane euthanasia,
spleens and spinal cords were prepared as described
previously [19]. Subsequently, single cell suspensions
were made. The cells were counted by trypan blue
exclusion and plated at the cell numbers indicated in
HL-1 medium (Lonza, Cologne, Germany).
Adoptive transfer experiments
For adoptive transfer experiments, spleen cells were pre-
pared from female SJL mice injected with PLPp/CFA
and PTX as described above at day 7 after immuniza-
tion. The resulting cells were incubated for three days in
HL-1 medium at 37°C, 5% CO2 with PLPp (concentra-
tion 20 μg/ml) alone or with PLPp plus CpG (concen-
tration 10 μg/ml). At the end of the incubation period
cells were washed carefully several times and 40 × 10
6
cells were injected intraperitoneally per recipient mouse.
Mice were assessed daily for the development of paraly-
tic symptoms, and the severity of disease was recorded
as described above.
Stimulation regimens, cytokine measurements by ELISPOT
and computer-assisted ELISPOT image analysis
ELISPOT assays were performed as described previously
[20]. Briefly, MultiScreen HTS-IP plates (Millipore,
Schwalbach, Germany) were coated overnight with the
capture antibodies in sterile PBS. All antibodies were
obtained from BD Pharmingen, San Diego, CA. The fol-
lowing coating antibodies were used: R4-6A2 was used
for IFN-g, JES6-1A12 was used for IL-2 and TC11-
18H10 was used for IL-17. Plates were blocked for 1 h
with sterile PBS/BSA 0,5% and washed 3× with sterile
PBS. Splenocytes were plated in HL-1 medium in tripli-
cate cultures each. Spinal cord single cell suspensions
were pooled from 3 to 4 animals and plated in HL-1
medium in duplicate wells. Thereafter cells were stimu-
lated with PLPp (final concentration of 20 μg/ml), with
CpG (final concentration of 10 μg/ml) or with both
agents. Subsequently plates were incubated at 37°C, 5%
CO2 for 16 h. After washing with PBS followed by PBS/
BSA 0,5%, detection antibodies were added overnight.
Biotinylated XMG1.2 was used for IFN-g, biotinylated
JES6-5H4 was used for IL-2, biotinylated TC11-8H4.1
was used for IL-17. The plate bound second antibody
was then visualized by adding streptavidin-alkaline phos-
phatase (SAV-AP, DAKO, Glostrup, Denmark) and
NBT/BCIP substrate (Bio-Rad, Munich, Germany).
Image analysis of ELISPOT assays was performed with
the ImmunoSpot™ Analysis Software after scanning the
plates with an ImmunoSpot™ Analyzer (CTL-Europe,
Bonn, Germany). In brief, digitized images of individual
wells of the ELISPOT plates were analyzed for cytokine
spots, based on the comparison of experimental wells
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(immune cells, no stimuli). After separating spots that
touched or partially overlapped, non-specific ‘back-
ground noise’ was gated out by applying spot size and
circularity analysis as additional criteria. Then, spots
that fell within the accepted criteria were highlighted
and counted. Single wells which could not be enumer-
ated because of confluence phenomena were assessed by
using the highest numbers of cytokine-producing cells
which could be regularly counted in other wells in the
same assay as an approximated estimate.
Statistical analysis
For statistical analysis, the two-sided t-test for different
variances (GraphPad PRISM 4 software, La Jolla, USA)
was used. Differences at p < 0.05 were considered statis-
tically significant.
Results
Injection of SJL mice with PLPp/CPG/IFA does not result
in clinical disease
To study the impact of TLR9 stimulation during the
priming of the autoreactive T cell response, we immu-
nized SJL mice with PLPp emulsified in CpG/IFA
(PLPp/CpG/IFA). In contrast to the mice immunized
according to the standard protocol at the same time, no
clinical signs of EAE were observed (Figure 1), consis-
tent with previously reported results by others [21;22].
No signs of EAE were seen during the entire observa-
tion period of 90 days. SJL mice immunized with PLPp
in CFA and 2 subsequent applications of PTX (PLPp/
CFA/PTX) developed severe EAE.
Injection of SJL mice with PLPp/CPG/IFA results in a
PLPp-specific Th1 response, but not a Th17 response
To investigate whether autoantigen specific T lympho-
cytes are present in the peripheral lymphatic tissue of
mice immunized with PLPp/CpG/IFA, measurements of
cytokine expression (IFN-g, IL-2, IL-17) in the spleens
of animals were conducted by ELISPOT at day 14 after
immunisation. High numbers of IFN-g- (mean: 104.67,
SD: 42.82) and IL-2- (mean: 168.72, SD: 73.44) produ-
cing cells were identified after restimulation with PLPp
(Figure 2A and 2B). Combined stimulation with PLPp
and CpG led to strong up-regulation of IFN-g produc-
tion (mean: 626.31, SD: 370.19) in comparison to stimu-
lation with PLPp alone (p < 0.01), but the number of
IL-2 producing cells (mean: 188.28, SD: 64.79) did not
change significantly. Almost no IL-17 producing cells
(mean: 4.19, SD: 3.22) were present in the spleens of
mice immunized according to the alternative protocol
(Figure 2C). Additional stimulation with CpG did not
lead to induction of higher numbers of IL-17 secreting
cells (mean: 2.33, SD: 2.52).
CpG enhance PLPp-specific IFN-g production in spleens of
mice during acute EAE, but have no effect on PLPp-
specific IL-17 production
To assess the impact of TLR 9 ligation on PLPp-specific
cytokine responses in the spleens of mice immunized
according to the standard (PLPp/CFA/PTX) protocol,
we conducted measurements on splenocytes of mice
sacrificed on day 12 after EAE induction. High frequen-
cies of IFN-g- (mean: 183.24, SD: 143.62) and IL-2-pro-
ducing (mean: 519.09, SD: 384.08), PLPp-specific T cells
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Figure 1 Representative disease course of SJL mice. 5 mice were immunized with PLPp/CFA with addition of pertussis toxin. 5 mice were
immunized with PLPp and CpG in IFA. The mean clinical EAE score is shown with standard deviation. The differences in disease scores between
the two groups on days 10, 11 and 12 were highly significant (p < 0.001).
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after recall with PLPp. The presence of CpG had a con-
siderable superadditive effect on the number of IFN-g-
producing cells (mean: 809.43, SD: 367.45), p = 0.0012
for PLPp vs. PLPp+CpG), but no effect on IL-2 produc-
tion (mean: 519.48, SD: 415.49) (Figure 3). These find-
i n g sa r ec o m p a r a b l et oc y t o k i n er e s p o n s e so f
splenocytes isolated out of mice immunized with PLPp/
CpG/IFA at day 14. ELISPOT measurements showed
that splenocytes of mice, in which EAE was successfully
induced, produced IL-17 after restimulation with PLPp
(mean: 172.33, SD: 103.68). However, CpG did not
increase the number of IL-17-producing, antigen specific
T cells (mean: 110.67, SD: 40.99) in splenocytes.
CpG potentiate both autoantigen-specific IFN-g and IL-17
production locally in the CNS during acute EAE
To study the impact of microbial components on cyto-
kine responses in the CNS in acute EAE, pooled spinal
cord single cell suspensions from mice with acute EAE
at day 12 were restimulated with PLPp and CpG and
the frequencies of cytokine-producing cells were deter-
mined by ELISPOT (Figure 4). Without antigen stimula-
tion, residual IL-17 (mean: 780, SD: 197.99) and IFN-g
(mean: 145, SD: 148.49) production was detected,
reflecting the activity of primed T cells in situ stimu-
lated by endogenous antigen. With external PLPp stimu-
lation, dominant IL-17 production (mean: 2465, SD:
1124.3) was detected, accompanied by IFN-g (mean:
1505, SD: 7.07) and (less) IL-2 (mean: 755, SD: 77.78)
production. Additional stimulation with CpG led to a
strong upregulation of IFN-g secretion in the target
organ (mean: 7485, SD: 1378.86, p < 0.01 for PLPp vs.
PLPp+CpG), as well as a moderate upregulation of IL-
17 production (mean: 6320, SD: 56.57, p = 0.01 for
PLPp vs. PLPp+CpG), but had no effect on IL-2 produc-
tion (mean: 515, SD: 219.2, p = ns). Stimulation with
CpG only (without addition of external PLPp) led to
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Figure 2 Frequencies of IFN-g (A), IL-2 (B) and IL-17 (C) producing cells in spleen cells of animals immunized with PLPp in CpG/IFA
after stimulation with PLPp, CpG or combined activation. Spleens were isolated on day 14 after immunization, and single cell suspensions
were made as described in Materials and Methods. Cells were plated at a density of 1.000.000 cells per well. The cumulative data of 7 animals
tested individually in two independent experiments are shown. Measurements were conducted in triplicate wells each. Each data point indicates
one individual animal, lines represent the mean. p values are given in Section 3.
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(mean: 2715, SD: 261.63, p = 0.014 for CpG vs. back-
ground), but did not affect spontaneous IFN-g (mean:
85, SD: 35.36, p = ns) or IL-2 (mean: 315, SD: 49.5, p =
ns) production of the inflammatory CNS isolate. As a
consequence, the IFN-g/IL-17 ratio substantially differed
depending on the type of stimulation (background: 0.19,
PLPp: 0.61, PLPp+CpG: 1.18, CpG: 0.03).
CpG oligonucleotides do not essentially alter the
encephalitogenicity of in-vitro-stimulated PLPp-specific T
cells pre-primed in the immune periphery
To investigate the impact of additional CpG stimulation
on pre-primed PLPp-specific T cells in vitro,a d o p t i v e
transfer experiments were conducted. Female SJL mice
were immunized with PLPp/CFA and PTX with the
standard protocol described above. On day 7 after
immunization (when the immune response in the per-
iphery was well established) these mice were sacrificed
and their spleen cells were taken in culture (either with
PLPp or with PLPp/CpG). After three days of culture,
the remaining viable cells were transferred into recipient
female SJL mice which also had been immunized with
PLPp/CFA and PTX with the standard protocol. To get
more differentiated information, one set of animals was
injected at day 9 after immunization (when disease just
started in some animals), another set was injected at day
10 after immunization (when disease was already estab-
lished). A control group at day 9 and day 10 each
received PBS only, no cells. As can be seen from Figure
5A-C, disease was quite severe in all groups in this set
of experiments, and even in the control group most ani-
mals eventually died after a fairly short time (the disease
course of all animals is depicted individually). In both
groups which received cells restimulated with PLPp one
animal each survived (in contrast to the respective
group receiving cells restimulated with PLPp/CpG). This
could (carefully) be interpreted as further evidence for
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Figure 3 Frequencies of IFN-g (A), IL-2 (B) and IL-17 (C) producing cells in spleens of animals immunized with PLPp in CFA and
pertussis toxin after stimulation with PLPp, CpG or combined activation. Spleens were isolated on day 12 after immunization, and single
cell suspensions were made as described in Materials and Methods. Cells were plated at a density of 1.000.000 cells per well. The cumulative data
of 7 animals tested individually in two independent experiments are shown. Measurements were conducted in triplicate wells each. Each data
point indicates one individual animal, lines represent the mean. p values are given in Section 3.
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of already primed PLPp-specific T cells. However, there
was not a fundamental alteration of disease into a nega-
tive or positive fashion affecting the majority of animals.
Discussion
The principal goal of this study was to investigate how a
microbial immune stimulant associated with a systemic
infection can influence the cytokine signature of an
ongoing autoimmune reaction in CNS autoimmune dis-
ease. The focus hereby was (1) on potential differences
between immune periphery and the CNS and (2) on dis-
tinct effects regarding Th1 and Th17 cells. The human
clinical situation to which the results of our EAE-based
study might apply is the mechanism via which a sys-
temic infection might worsen ongoing CNS autoimmune
pathology in MS and thereby cause disease progression
or relapse [6-9]. As a paradigmatic microbial stimulus
simulating “infection” in our study CpG oligonucleotides
were investigated regarding their co-stimulating effect
on the PLPp-specific cytokine signature in PLPp-
induced EAE in SJL mice. We concentrated on the
situation in acute EAE by measuring the quantity of
PLPp-specific IFN-g-, IL-2- and IL-17-producing cells in
the immune periphery and the target organ CNS. The
presence of microbial factors, in particular TLR stimu-
lants, can have different effects on the immune system
when it happens initially during the priming of the auto-
immune reaction [22-24] in contrast to its appearance
during the actual autoimmune disease [11;12;25;26]. It
has been demonstrated by two previous studies that
mice injected with PLPp/CPG do not develop clinical
EAE, but a strong PLPp-specific Th1 response [21;22].
Our data confirms these observations, as well as the fact
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C
Figure 4 Frequencies of IFN-g (A), IL-2 (B) and IL-17 (C) producing PLPp specific cells in spinal cords of animals immunized with PLPp
in CFA and pertussis toxin after stimulation with PLPp, CpG or combined activation. Spinal cords were isolated on day 12 after
immunization, and single cell suspensions were made as described in Materials and Methods. Cells were plated at a density of 100.000 cells per
well. Raw data is adjusted to 1.000.000 cells per well for a direct comparison with frequencies of cytokine-producing spleen cells. Each bar
represents two independent experiments with pooled spinal cord cultures of totally 7 mice (4 mice in the first experiment, 3 mice in the second
experiment) due to the small number of mononuclear cells which can be recovered the CNS. Measurements were conducted in duplicate wells
each. p values are given in Section 3.
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response after this injection protocol. In contrast to one
of these previous works [22] however, we want to avoid
the simplistic conclusion that the mere absence of Th17
cells explains the lack of clinical disease symptoms. The
same group which has initially described the adjuvant
effect of CpG in EAE [21] has demonstrated that EAE
can be induced in the absence of Th17 cells, and that
Th1 cells cannot automatically be seen as protective,
but induce a different type of CNS pathology than do
Th17 cells [15].
Under the conditions of established CNS-autoantigen-
specific immunity, CpG oligonucleotides effectively
enhance PLPp-specific IFN-g production in splenocytes,
i.e. the immune periphery. Since they also trigger IFN-g
without PLPp, this appears to be (partially) a stimulating
effect on the non-T-cell compartment, presumably
monocytes and macrophages. However, combined sti-
mulation (PLPp and CpG) results in an over-additive
effect, which is more than the sum of the single stimula-
tions with PLPp or CpG alone. This is not dependent on
the presence of clinical EAE symptoms - the effect is the
same both in healthy animals after injection with PLPp/
CpG/IFA and in animals with severe EAE after injection
with PLPp/CFA and PTX. No effect is seen in both ani-
mal groups on PLPp-specific IL-2 and IL-17 production,
neither alone or with combined stimulation. Therefore,
the effect of TLR9 ligation on the autoreactive T cell
population in the periphery does not clarify its disease-
enhancing effect in EAE which has been described by
others [11]. In contrast, in the inflamed CNS a complex
picture emerges: Already stimulation with CpG alone
(without addition of PLPp) triggers strong IL-17 produc-
tion, but no IFN-g production. With combined stimula-
tion (CPG and PLPp), a strong enhancement of both
IFN-g and IL-17 occurs, whereas IL-2 production is not
essentially altered at any stimulation condition. Since in
the spinal cord, which was isolated directly ex vivo,c o n -
siderable amounts of endogenous antigen are likely to
be presented by local APC, there is most likely no pure
TLR9 stimulation, but also combined stimulation when
only CpG are experimentally applied. This explains why
there is already considerable residual cytokine produc-
tion without external stimulant, with IL-17 being the
dominant cytokine. CpG might enhance the already
existing Th17 response, but might also activate cells of
the innate immune system which are able to produce
IL-17. In any case, these cells are in EAE only present in
the inflamed CNS, not in the immune periphery, or they
can only be activated in the inflamed CNS. This indi-
cates that one immunological stimulus (CpG) can have
substantially different effects on the cytokine architec-
ture in distinct stages of an autoimmune reaction. TLR9
stimulation alone during priming is not sufficient to
Figure 5 Adoptive transfer of PLPp-stimulated and PLPp/CpG-
stimulated PLPp-specific T cells into SJL mice with actively
induced EAE. Female SJL mice injected with PLPp/CFA and PTX as
described above were (either at day 9 or day 10) injected with cells
re-stimulated in vitro either with PLPp (A) or PLPp/CpG (B). A control
group received PBS at day 9 or day 10, respectively (C). The disease
course of all animals is depicted individually. Further details are
described in the results section.
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effect on IL-17 production in the inflamed target organ
in situ under various local conditions. This is paralleled
by the observation that in vitro co-stimulation of periph-
erally primed PLPp-specific T cells with CpG does not
essentially alter the encephalitogenic potential of these
cells in adoptive transfer experiments.
As a main conclusion of this set of data, within the
CNS, microbial stimulants might cause very heteroge-
neous and patchy micro-effects. Both the presence of
an infectious stimulus and the amount of CNS autoan-
tigen locally present might determine the IFN-g/IL-17
ratio which results. External addition of PLPp (which
might yield unrealistic concentrations which do not
occur in vivo) causes a strongly different IFN-g/IL-17
ratio than the culture with endogenous PLPp only. A
landmark study has suggested that the local IFN-g/IL-
17 ratio in the individual lesions determines disease
progression and depends on the anatomic site of the
lesion [27]. Therefore, different inflammatory lesions
i nt h es a m eC N Sm i g h tb ed i f f e r e n t i a l l ya f f e c t e db yt h e
presence of a microbial stimulus, depending on auto-
antigen availability and other local factors. This might
be in line with the heterogeneity of MS lesions in one
and the same patient. For the potential connection
between infection and worsening of already ongoing
CNS autoimmune disease, our results suggest that the
crucial effect of inflammatory mediators is achieved in
the CNS in situ. A scenario is possible where traces of
low molecular pathogenic factors present in abundance
in peripheral compartments (e.g. blood, spleen, lym-
phatic tissues) during a systemic inflammation enter
the brain and lead in cooperation with local ongoing
autoimmune processes to reactivation of quiescent or
suppressed autoantigen-specific T cells. These acti-
vated memory cells recruit other antigen-specific and
bystander immune cells from the peripheral pool caus-
ing thereby an acute relapse or disease progression.
This concept is supported by observations by other
groups [11;12;25]. One of these studies even claims
that endogenous, non-microbial TLR9 ligands like
phosphodiester DNA (which might arise in the course
of the autoimmune process) might substitute for
microbial TLR9 ligands and thereby further local auto-
immune pathology [11].
Of note, it is not the purpose of our study to support
argumentation for a unidimensional pathogenic role for
one single cytokine, neither for IL-17 nor for IFN-g.I n
the light of the current literature on EAE and other
experimental autoimmune diseases, different cytokines
can induce different types of autoimmune pathology
[15;16;28]. We conclude that (1) CpG can have different
effects on T cell cytokine production depending on
whether they are present in the priming phase or during
the ongoing autoimmune response (2) the effects in the
immune periphery and in the inflamed CNS differ quali-
tatively and quantitatively and (3) in the CNS, condi-
tions of the local microenvironment like the amount of
antigen additionally determine the cytokine signature.
An organism with an ongoing autoimmune response in
which additionally infectious agents and their microbial
stimuli are present is likely to be an anatomically quite
heterogeneous “mosaique” regarding the cytokines
which dominate ongoing local autoimmunity, in particu-
lar in the inflamed target organ. Simple mechanistic
extrapolations towards the human disease MS currently
therefore do not seem justified, in particular not for one
single molecular receptor or ligand. Additional studies
have to clarify which cellular compartments in the CNS
are producing the respective cytokines and how they
change under the influence of exogenous/endogenous
TLR ligands during the various stages of the course of
the autoimmune disease.
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